NovoTHOR® is a systemic PhotobiomodulationTherapy used by Olympic athletes, professional NFL, MMA, and NBA players to aid their recovery and keep them at peak performance.
Our mission at the AIM Clinic is to bring the best therapies being used by top athletes, such as NovoTHOR®, and make it available to our local community to help reduce chronic disease and pain and enable true healing.
Photobiomodulation: Photobiomodulation therapy (PBM Therapy) is the application of monochromatic light to improve the speed and quality of tissue repair through modulation of inflammation by enhancing mitochondrial function. The NovoTHOR® delivers 480 watts of power to the body using the wavelengths 660 nm (Red) & 850 nm (Near-Infrared). The goal is to boost energy, increase immunity, decrease inflammation, and activate stem cells for healing. Treatments are 5-20 minutes based on tolerance because it can trigger a Herxheimer and/or Detox reactions for some patients.
The Science on How it Works: Most of the effects of PBM Therapy can be explained by light absorption in the mitochondria [1-3]. Nearly every cell in the body has lots of mitochondria (hundreds or thousands per cell). Mitochondria make cellular energy (ATP) from oxygen and pyruvate. In stressed or ischemic tissues, mitochondria make their own nitric oxide (mtNO) [4-6] which competes with oxygen. The nitric oxide binds to Cytochrome c Oxidase (CcO) (the terminal enzyme in the electron transport chain) and displaces oxygen . This displacement of oxygen has two negative effects; reduced ATP synthesis and increased oxidative stress (leading to inflammation via the inflammatory “master switch” NF-kB) [4-6, 8-10]. Many of the cascading benefits can be found in the below graph:
The benefit on the mitochondria can even be seen visually. With the dosage of light therapy through, regular mitochondria can be transformed into “Giant Mitochondria” as seen in “b” of the below microscopic picture vs “a” which did not receive light therapy. The sources of mitochondria in our bodies include stem cells, immune cells, muscle cells, nerve cells, and brain cells which can also explain the diverse benefits seen with NovoTHOR® therapy.
FDA Clearance: NovoTHOR® is a Class I Medical Devices. NovoTHOR® is built according to current Good Manufacturing Practices (cGMP) and is in compliance with applicable standards as required by FDA.
References: 1. Karu, T.I., Mitochondrial signaling in mammalian cells activated by red and near-IR radiation. Photochem Photobiol, 2008. 84(5): p. 1091-9.
2. Eells, J.T., et al., Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy. Mitochondrion, 2004. 4(5-6): p. 559-67.
3. Karu, T., Mitochondrial mechanisms of photobiomodulation in context of new data about multiple roles of ATP. Photomedicine and Laser Surgery, 2010. 28 (2): p. 159-60.
4. Palacios-Callender, M., et al., Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proceedings of the National Academy of Sciences of the United States of America, 2004. 101 (20): p. 7630-5.
5. Cleeter, M.W., et al., Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS letters, 1994. 345(1): p. 50-4.
6. Antunes, F., A. Boveris, and E. Cadenas, On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. Proc. Natl. Acad. Sci. USA, 2004. 101: p. 16774-9.
7. Galkin, A., A. Higgs, and S. Moncada, Nitric oxide and hypoxia. Essays in biochemistry, 2007. 43: p. 29-42.
8. Lane, N., Cell biology: power games. Nature, 2006. 443(7114): p. 901-3.
9. Bolanos, J.P., et al., Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes. Journal of neurochemistry, 1994. 63(3): p. 910-6.
10. Chen, S., Natural products triggering biological targets--a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Current drug targets, 2011. 12(3): p. 288-301.